ClinicalTrials.gg
Status unknownNCT03549299Updated Oct 7, 2022

Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD

A Phase 1/2 interventional study of LSC2 in Limbal Stem Cell Deficiency, sponsored by RHEACELL GmbH & Co. KG. Status unknown at 5 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-10-07.

Sponsored by RHEACELL GmbH & Co. KG · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The aim of this clinical trial is to investigate the efficacy (by monitoring neovascularization and epithelial defects) of up to four doses of the investigational medicinal product (IMP) LSC2 topically administered on the target eye of patients with LSCD. Further, safety of the IMP during and after application will be investigated (by monitoring adverse events [AEs]).

Read the detailed description

This is an interventional, open-label, phase I/IIa clinical trial to investigate the efficacy and safety of up to four doses of the IMP topically administered on the target eye of patients with LSCD. Patients will be treated in up to four ascending dose groups.

The allogeneic investigational product LSC2 contains ABCB5-positive limbal stem cells (from corneal rims of cadaveric donors, expanded ex vivo, isolated and stored in a donor cell bank).

The IMP will be applied on the target eye. Prior to application, the conjunctival pannus will be removed under general or local anesthesia.

Patients will be followed up for efficacy for 1 year. Efficacy of the IMP will be monitored by assessing neovascularization and epithelial defects.

To assess long-term safety of LSC2 one follow-up visit at Month 24 post IMP application is included.

02

Conditions studied

  • Limbal Stem Cell Deficiency

Keywords

  • limbal stem cell deficiency
  • ABCB5
  • Limbal stem cells
  • LSCs
  • LSC
  • allogeneic
  • tissue engineered product
  • phase I/IIa
03

In context

Limbal Stem Cell Deficiency

38 studies on the registry are indexed under Limbal Stem Cell Deficiency; 15 are open to participants now.

This study's planned enrollment of 16 is below the median of 20 across 23 interventional studies indexed under Limbal Stem Cell Deficiency.

Browse Limbal Stem Cell Deficiency studies →

Lead sponsor

RHEACELL GmbH & Co. KG is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged 18 to 85 years
  2. Patients with secondary bilateral or unilateral LSCD (injury that caused LSCD at least 6 months prior to inclusion)
  3. Neovascularization: Vessel penetration of at least 2 quadrants, with central cornea involved
  4. Patients understand the nature of the procedure and are providing written prior to any clinical trial procedure
  5. Women of must have a negative blood pregnancy test at Visit 1
  6. Women of childbearing potential must be willing to use highly effective methods during the course of the clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Compromised eyelid mobility and/or symblepharon; patient can be re-screened after appropriate treatment
  2. Presence of eyelid malposition; patient can be re-screened after appropriate treatment
  3. Active local ocular or systemic infection and/or inflammation. Patient can be re-screened after infection and/or inflammation is resolved.
  4. Tumor diseases or history of tumor disease
  5. Active ocular neoplastic disease (exclusion will be based on investigator's assessment)
  6. Corneal erosion or ulcer is bigger than 4 mm2; corresponding to less than 95% of continuous corneal epithelium. Patient can be re-screened after erosion or ulcer is resolved (≤ 4 mm2).
  7. Positive for (HIV) 1 and/or 2 (diagnosed by serologic testing)
  8. or unstable concurrent disease or other clinical to stem cell transplantation
  9. History of glaucoma
  10. Contraindications to trial related procedures/substances including

    1. The surgical procedure (e.g. removing of the conjunctival pannus)
    2. Contact lens complications due to contact lens use in the proposed trial (based on the Efron Grading scale for standard clinical reference for contact lens complications)
    3. Tear secretion deficiency determined by Schirmer's test
    4. Allergy, sensitivity or intolerance to components/ of the IMP/ per protocol pre-planned concomitant medications
    5. Conjunctival scarring with fornix shortening
    6. General anesthesia (in case general anesthesia is required) or local anesthesia
    7. (being mandatory concomitant therapy)
  11. Intraocular pressure (IOP) of ≥30 mm Hg
  12. History or clinical signs of stroke or
  13. Active or suspected ocular or periocular infections
  14. Active or suspected intraocular inflammation
  15. Further clinical contraindications to IMP application (exclusion will be based upon investigator's judgment)
  16. Current or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial
  17. Previous participation in this clinical trial (except screening failure due to inclusion criterion 2 and/or exclusion criterion 1 and/or 2 and/or 3 and/or 6)
  18. Known abuse of alcohol, drugs, or medicinal products
  19. Patients unwilling or unable to comply with the requirements of the protocol
  20. Lactating women
  21. Evidence of any other medical conditions (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment
  22. Employees of the sponsor, or employees or relatives of the investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    LSC2; 7.5 x 10^4 cells

    Single dose of LSC2, 7.5 x 10\^4 cells per patient

    Biological: LSC2

  • Experimental
    LSC2; 3.0 x 10^5 cells

    Single dose of LSC2, 3.0 x 10\^5 cells per patient

    Biological: LSC2

  • Experimental
    LSC2; 8.0 x 10^5 cells

    Single dose of LSC2, 8.0 x 10\^5 cells per patient

    Biological: LSC2

  • Experimental
    LSC2; 1.2 x 10^6 cells

    Single dose of LSC2, 1.2 x 10\^6 cells per patient

    Biological: LSC2

Interventions

  • BiologicalLSC2

    Topical application of IMP on target eye

    Also known as: Suspension of ABCB5-positive limbal stem cells in pre-filled syringe

06

What researchers measure

Primary outcomes

  1. Response rate at 12 months after IMP application

    Response rate at 12 months after IMP application, where response is defined as: * no or mild corneal neovascularization (no vessel penetration or vessel penetration up to 1 quadrant, without central cornea) AND * no or mild epithelial defects (no corneal erosion or ulcer are present (corneal wounds are closed) or minimal superficial staining)

    Time frame: Month 12

  2. Assessment of adverse event (AE) occurrence

    All AEs occurring during the clinical trial will be registered, documented and evaluated.

    Time frame: Up to 24 months.

Secondary outcomes

  1. Response rate at 3 months after IMP application

    Response rate at 3 months after IMP application, where response is defined as: * no or mild corneal neovascularization (no vessel penetration or vessel penetration up to 1 quadrant, without central cornea) AND * no or mild epithelial defects (no corneal erosion or ulcer are present (corneal wounds are closed) or minimal superficial staining)

    Time frame: Month 3

  2. Neovascularization

    Corneal neovascularization will be assessed as "none" (no blood vessel penetration), "mild" (blood vessel penetration of 1 quadrant, without central cornea involvement), "moderate" (blood vessel penetration of 1 quadrant, with central cornea involvement or blood vessel penetration of 2 or 3 quadrants, with or without central cornea involvement) or "strong" (blood vessel penetration of all quadrants, with or without central cornea involvement).

    Time frame: Baseline, week 1, 2, 3, 4, 5, 6, 7, 12, month 6 and 12

  3. Epithelial defects

    Epithelial defects will be assessed as "none" (no corneal erosion or ulcer are present (corneal wounds are closed)) or "mild" (minimal superficial staining) or "moderate" (dense coalescent staining up to 2 mm in diameter) or "strong" (dense coalescent staining greater than 2 mm in diameter) by means of fluorescein staining.

    Time frame: Baseline, week 2, 4, 6, month 3, 6 and 12

  4. Ocular symptoms of pain, photophobia, burning

    Photophobia and burning will be assessed as "no complaint" (grade 0), "mild" (grade 1), "moderate" (grade 2) or "severe" (grade 3). Pain assessment will be done by the patient using a 11-point numerical rating scale ranging between no pain (zero) and worst imaginable pain (ten).

    Time frame: Baseline, week 2, 4, 6, 12, month 6 and 12

  5. Ocular inflammation

    The assessment of inflammation will be categorized as present (yes) or nonexistent (no).

    Time frame: Baseline, week 2, 4, 6, 12, month 6 and 12

  6. Corneal opacity

    Corneal opacification will be assessed as "none" (no corneal opacification), "mild" (corneal opacification in up to 1 quadrant, without central cornea involvement), "moderate" (corneal opacification in 1 quadrant, with central cornea involvement or corneal opacification in 2 or 3 quadrants, with or without central cornea involvement) or "strong" (corneal opacification in all quadrants, with or without central cornea involvement). Additional densitometric Pentacam® measurements are optional. Opacity values of the following ring-shaped corneal segments will be record: * 0 - 2 mm, 2 - 6 mm, 6 - 10 mm, 10 - 12 mm (anterior, central and posterior corneal layer for each segment) * 0 - 2 mm, 2 - 6 mm, 6 - 10 mm, 10 - 12 mm (full thickness average for each segment) * Anterior layer of the complete cornea (0 - 12 mm) * Central layer of the complete cornea (0 - 12 mm) * Posterior of the complete cornea (0 - 12 mm) * Overall cornea (0 - 12 mm, full thickness)

    Time frame: Baseline, week 2, 4, 6, 12, month 6 and 12

  7. Visual acuity

    Clarity of vision.

    Time frame: Baseline, week 2, 4, 6, 12, month 6 and 12

  8. Quality of life assessment

    Quality of life (visual function questionnaire-25 \[VFQ-25\]) questionnaire to be answered.

    Time frame: Baseline, week 12, month 12

  9. Physical examination

    A full physical examination will be performed at week 12 and abnormal physical examination results will be evaluated and reported as AEs.

    Time frame: Baseline, week 12, month 12

  10. Tonometry

    Time frame: Baseline,week 1, 3, 7 and 12

  11. Vital signs: Body temperature at Baseline, week 12, month 12

    Body temperature at Baseline, week 12 and month 12 will be evaluated.

    Time frame: Baseline, week 12, month 12

  12. Vital signs: Blood pressure at Baseline, week 12, month 12

    Blood pressure at Baseline, week 12 and month 12 will be evaluated.

    Time frame: Baseline, week 12, month 12

  13. Vital signs: Heart rate at Baseline, week 12, month 12

    Heart rate at Baseline, week 12 and month 12 will be evaluated.

    Time frame: Baseline, week 12, month 12

07

Study locations

5 sites
  • Massachusetts Eye and Ear Infirmary
    Boston, Massachusetts 02114, United States
  • Universitäts-Klinikum Heidelberg, Kopfklinik
    Heidelberg, 69120, Germany
  • Universitäts-Klinikum Jena, Augenklinik
    Jena, 07747, Germany
  • Universitäts-Klinikum Köln, Augenklinik
    Köln, 50937, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Augenklinik und Poliklinik
    Mainz, 55131, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2019 (actual). Primary completion is estimated for Sep 2023, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
Jun 8, 2018
StartActual
Jul 4, 2019
Primary completionEst.
Sep 2023
CompletionEst.
Sep 2023
Last update
Oct 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03549299
Lead sponsor
RHEACELL GmbH & Co. KG
Collaborators
FGK Clinical Research GmbH, Ticeba GmbH, Granzer Regulatory Consulting & Services
Responsible party
Sponsor
First posted
Jun 8, 2018
Start date
Jul 4, 2019
Primary completion
Sep 2023 (estimated)
Completion
Sep 2023 (estimated)
Last update
Oct 7, 2022

Study contacts

Gerd U. Auffarth, Prof.Dr.med.
principal investigator · Universitäts-Klinikum Heidelberg, Kopfklinik, Heidelberg, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion